2011 and 2012 have been good years but the rate of innovation in drug development is anything but healthy, a venture investor focusing on the life sciences said yesterday at the U.S. Conference on Rare Diseases and Orphan Products underway this week in Washington DC. read more >
The regulatory pathway that we have learned from rare diseases is now becoming the paradigm in general, FDA Deputy Commissioner Stephen P. Spielberg, MD, PhD, said this morning in the opening session of Day 2 of the U.S. Conference on Rare Diseases and Orphan Products.
From Left to Right: Mary Dunkle- NORD, Christy Greeley- Cystinosis Research Network, Ron Bartek-Friedrich’s Ataxia Research Alliance, Jeff Wuchich- Alternating Hemiplegia of Childhood Foundation, Mirta Avila Santos, American Behcet’s Disease Association (ABDA), Sandy McElgunn- ABDA, Megan O’Boyle- Phelan-McDermid Syndrome Foundation
Within the first hour of the Annual DIA-NORD U.S. Conference on Rare Diseases & Orphan Products, NORD and DIA hosted a panel of six patient advocates to help remind everyone that patients are at the heart of everything we will be talking about in the next few days.